CClinicalTrials.gg
CompletedNCT03309189CHildHNSUpdated Jul 13, 2018

Swiss Childhood Health and Nutrition Survey

An observational study in Overweight and Obesity in Schoolchildren, sponsored by Isabelle Herter-Aeberli. Completed at 1 site in Switzerland. Open to participants aged 6 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-13.

Sponsored by Isabelle Herter-Aeberli · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
2,292
Ages
6 Years to 12 Years
Sex
All
01

Study summary

The aim of the present study is to assess the prevalence of overweight and obesity in 6 to 12 year old children in Switzerland. This data will be used to investigate trends in the development of overweight and obesity in Switzerland. In addition, a questionnaire will be used to assess data on physical activity, nutrition, health and socioeconomic background and waist circumference as well as skin fold thicknesses will be measured.

02

Conditions studied

  • Overweight and Obesity in Schoolchildren

Browse trials for

03

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

All children at the selected schools and in the defined age range are eligible.

Inclusion criteria

  • age between 6 and 12 years

Exclusion criteria

Exclusion Criteria:

  • none
04

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
2,292 participants (actual)
Patient registry
No
05

What researchers measure

Primary outcomes

  1. Prevalence of overweight and obesity

    Based on weight and height measurements BMI z-scores will be calculated for the classification in the different weight status groups (underweight, normal weight, overweight, obese)

    Time frame: 1 day of first visit

Secondary outcomes

  1. Waist circumference

    Time frame: 1 day of first visit

  2. body fat %

    Based on the measurement of skinfold thicknesses at 4 sites body fat % will be calculated

    Time frame: 1 day of first visit

  3. Physical activity

    Assessed using a questionnaire

    Time frame: 1 day of first visit

  4. Nutrition

    Assessed using a questionnaire

    Time frame: 1 day of first visit

  5. General health

    Assessed using a questionnaire

    Time frame: 1 day of first visit

  6. Socioeconomic background

    Assessed using a questionnaire

    Time frame: 1 day of first visit

Other outcomes

  1. Age

    Assessed using a questionnaire

    Time frame: 1 day of first visit

  2. Gender

    Assessed using a questionnaire

    Time frame: 1 day of first visit

06

Study locations

1 site
  • ETH Zurich
    Zürich, 8092, Switzerland
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03309189
Lead sponsor
Isabelle Herter-Aeberli
Responsible party
Isabelle Herter-Aeberli (Senior Scientist, Swiss Federal Institute of Technology) — Sponsor-investigator
First posted
Oct 13, 2017
Start date
Aug 17, 2017
Primary completion
Mar 31, 2018
Completion
Jun 30, 2018
Last update
Jul 13, 2018

Study contacts

Isabelle Herter, PhD
principal investigator · ETH Zurich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion